Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Inclusion Criteria * Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. * Age ≥ 18 years at the time of consent. * Body weight \> 30 kg. If body weight falls to 30 kg or below during the study, the subject will be removed from study drugs. * ECOG Performance Status of 0-1 within 7 days prior to registration. * Life expectancy of ≥ 12 weeks. * Histological or cytological evidence of stage IV Kras mutation positive non-squamous NSCLC. * Patients who have recurrence following treatment for earlier stages of NSCLC are eligible provided the recurrence has not occurred within 12 months of completing prior therapy. * Patient's tumor must be known to be PD-L1 high (≥ 50%). SP-142 assay will not be accepted. See Section 8.1 for additional information regarding this result. * Measurable disease according to RECIST v1.1 criteria within 4 weeks of study registration. * Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 14 days prior to registration. * Absolute Neutrophil Count (ANC) ≥ 1.5 K/mm3 * Hemoglobin (Hgb) ≥ 9.0 g/dL * Platelets ≥ 75 k/mm3 * Calculated creatinine clearance ≥ 45 cc/min using the Cockcroft-Gault formula * Bilirubin ≤ 1.5 × upper limit of normal (ULN) This will not apply to subjects with clinical diagnosis of Gilbert's syndrome (persistent or recurrent hyperbilirubinemi…